The U.S. Patent and Trademark Appeal Board (PTAB) found all the claims in two formulation patents for Sanofi SA's Lantus (insulin glargine) unpatentable as the result of an inter partes review (IPR) requested by Mylan NV, of Hertfordshire, U.K.